Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Corvus Pharmaceuticals, Inc. Transaction History
Empirical Financial Services, LLC D.B.A. Empirical Wealth Management
- $4.37 Billion
- Q2 2025
A detailed history of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Empirical Financial Services, LLC D.B.A. Empirical Wealth Management holds 168,000 shares of CRVS stock, worth $771,120. This represents 0.02% of its overall portfolio holdings.
Number of Shares
168,000Holding current value
$771,120% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
107Shares Held
37.2MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$31.9 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$18.7 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$15 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$12.8 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$12.3 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $214M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...